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Background: Lipoprotein lipase regulates fat uptake into adipose tissue.
Results: A mouse model with increased adipose tissue lipoprotein lipase has improved glucose metabolism when challenged
with a high fat diet.
Conclusion: Increasing adipose tissue lipoprotein lipase improves adipose tissue function.
Significance: Adipose tissue lipoprotein lipase protects against obesity-induced glucose and insulin intolerance.
Lipid accumulation in liver and skeletalmuscle contributes to
co-morbidities associated with diabetes and obesity.Wemade a
transgenic mouse in which the adiponectin (Adipoq) promoter
drives expression of lipoprotein lipase (LPL) in adipocytes to
potentially increase adipose tissue lipid storage. These mice
(Adipoq-LPL) have improved glucose and insulin tolerance as
well as increased energy expenditure when challenged with a
high fat diet (HFD). To identify the mechanism(s) involved, we
determinedwhether theAdipoq-LPLmice diverted dietary lipid
to adipose tissue to reduce peripheral lipotoxicity, but we found
no evidence for this. Instead, characterization of the adipose
tissue of the male mice after HFD challenge revealed that the
mRNA levels of peroxisome proliferator-activated receptor-
(PPAR) and a number of PPAR-regulated genes were higher
in the epididymal fat pads of Adipoq-LPL mice than control
mice. This included adiponectin, whose mRNA levels were
increased, leading to increased adiponectin serum levels in the
Adipoq-LPLmice. In many respects, the adipose phenotype of
these animals resembles thiazolidinedione treatment except
for one important difference, the Adipoq-LPL mice did not
gain more fat mass on HFD than control mice and did not
have increased expression of genes in adipose such as glycerol
kinase, which are induced by high affinity PPAR agonists.
Rather, there was selective induction of PPAR-regulated
genes such as adiponectin in the adipose of the Adipoq-LPL
mice, suggesting that increasing adipose tissue LPL improves
glucose metabolism in diet-induced obesity by improving the
adipose tissue phenotype. Adipoq-LPL mice also have in-
creased energy expenditure.
Lipoprotein lipase (LPL)2 is a central enzyme in lipid metab-
olism and adipose biology. LPL is synthesized and secreted by
adipocytes andmuscle and is transported to the capillary endo-
theliumwhere it hydrolyzes the triglyceride (TG) core of circu-
lating very low density lipoprotein (VLDL) and chylomicrons.
The hydrolysis products are fatty acids and monoacylglycerol,
which are taken up by the tissue. Depending upon the circum-
stance, such as the fed or fasting state, LPL delivers fatty acids to
adipose tissue for storage or to heart and skeletal muscle as a
fuel source. Therefore, LPL activity is highly regulated in these
tissues, acting as a “metabolic gatekeeper” (1) to ensure that
fatty acids are delivered to the correct tissue depending upon
the physiological state (2).
In obesity, adipose tissue lipid accumulates up to a point, and
then lipid is stored in ectopic sites such as liver andmuscle. This
increases diacylglycerides (DAGs) and ceramides, which inhibit
insulin receptor signaling in these tissues (3). The accumulation
of these ectopic lipids is thus postulated to cause insulin resist-
ance along with inflammation and endoplasmic reticulum
stress (3–5). Consistent with its ability to promote ectopic lipid
accumulation, tissue-specific transgenic expression of LPL in
skeletal muscle and liver induces insulin resistance (6), and LPL
deficiency in muscle protects against insulin resistance in that
tissue (7). Adipose tissue protects against the accumulation of
ectopic lipids in these peripheral tissues by storing fat as neutral
lipid (triglyceride). Lipid diversion into adipose tissue is one of
the mechanisms of insulin sensitization by thiazolidinediones
(TZDs) (8, 9), and LPL is an important gene target of TZDs (10).
As expected, when there is insufficient adipose to store lipid,
such as in adipose-deficient mice and humans, insulin resist-
ance develops (11–13). Together, these observations suggest
that diversion of lipid frommuscle and liver into adipose tissue
is generally beneficial.
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In addition to lipid diversion, another predicted effect of
increased adipose LPL is stimulation of PPAR transcription fac-
tors by the free fatty acids generated by lipoprotein hydrolysis.
Depending upon the cell type and PPAR transcription factor
expressed, activation of PPARcanhave important physiological
consequences. For instance, in macrophages or endothelial
cells, LPL hydrolysis of VLDL activates PPAR transcription fac-
tors and has anti-inflammatory effects (14, 15). In muscle, LPL
stimulates PPAR, regulatingmitochondrial biogenesis (16). In
adipose tissue, LPL is in a positive feedback loop in which LPL
stimulates PPAR, and the LPL gene is induced by PPAR (10).
Activation of PPAR in adipose tissue could result in numerous
physiological outcomes, including insulin sensitization.
We have made a transgenic mouse in which the adiponectin
promoter drives the expression of LPL in adipocytes, and these
mice (Adipoq-LPL) have improved glucose tolerance and insu-
lin tolerancewhen challengedwith a high fat diet.We evaluated
whether this was due to reduction of ectopic lipids in skeletal
muscle and liver and/or activation of PPAR in adipose tissue.
We found that the adiponectin promoter used only modestly
increased adipose tissue Lpl over endogenous levels, which was
insufficient to cause a redistribution of lipid. However, there
was sufficient expression of the transgene to improve the white
adipose phenotype by increasing PPAR and PPAR-regulated
genes such as adiponectin, resulting in an improved phenotype
after HFD challenge.
EXPERIMENTAL PROCEDURES
Animal Studies—All of the studies involving mice were
approved by the University of Kentucky Institutional Animal
Care and Use Committee. The mice were housed in standard
conditions at 22 °C, with a 14-h light and a 10-h dark cycle, and
ad libitum access to standard rodent diet (Teklad Global 18%
protein rodent diet; 2018; Teklad, Madison, WI) and water.
Mice were given high fat diet (60% kcal from fat; D12492;
Research Diets, New Brunswick, NJ) at the indicated age. Body
composition was determined with an EchoMRI system (Echo
Medical Systems, Houston, TX). Mice were evaluated by indi-
rect calorimetry (TSE Systems, Chesterfield, MO). Wild-type
female C57B6/J mice (The Jackson Laboratory, Bar Harbor,
ME) were used for backcrossing.
Adipoq-LPL Transgenic Mouse—Human LPL was amplified
by PCR using primers that added a 5HindIII site and a BamHI
site in front of the stop codon using the LPL 3.6 plasmid (17) as
a template. The PCR product was then subcloned into the Hin-
dIII and BamHI sites of pCMV-14 to add a C-terminal
3FLAG epitope. Human LPL-3FLAG was then amplified
using a primer that added a ClaI site and 10 bases of its 5-un-
translated region, which corresponds to a strong Kozak
sequence, and a 3 primer that added an EcoRV site after the
FLAG epitope stop codon. This PCR product was subcloned
into theClaI-EcoRV site of adiponectin 5.4, which is a construct
that allows for very specific transgene expression in adipocytes
using a modified adiponectin promoter, from Dr. Philip
Scherer (18). The resultant plasmid was then digested with
XhoI and KpnI to release the adiponectin 5.4 promoter-hLPL-
3FLAG construct. This was used by the transgenic mouse
facility at theUniversity of Kentucky tomakeAdipoq-LPLmice;
there were several founder mice, but only one made detectable
transgene protein. Studies in this work were from mice back-
crossed 5–8 times intoC57BL6mice. Controlmicewere always
littermate controls.
Glucose and Insulin Tolerance Tests—Blood glucose was
measured using an AlphaTRAK glucometer (32004-02;
Abbott). For glucose tolerance tests, mice were moved to the
procedure room at least 4 h prior to the start of the procedure
and fasted with free access to water. The animals were then
weighed and intraperitoneally injected with D-()-glucose, 1
mg/kg body weight. Blood glucose levels were measured at
baseline (immediately prior to injection), and at 30, 60, 90, and
180min. For insulin tolerance tests, themicewereweighed, and
1.0–1.5 units Regular Human Insulin (Lilly) per kg of body
weight was injected into the intraperitoneal cavity; blood glu-
cose levels were determined at 0, 30, 60, 90, and 180 min.
Analysis of Serum—Adiponectin was quantified with an
ELISA from Alpco (Salem, NH). Insulin and leptin were quan-
tified usingMilliplexMultiplex assays (Merck) and imaged on a
Magpix system. Cholesterol was measured with a kit from
Pointe Scientific (Brussels, Belgium); NEFA and triglycerides
were determined with kits from Wako (Osaka, Japan). Serum
was also fractionated on a fast protein liquid chromatography
system to resolve lipoproteins as described (19).We then deter-
mined the area under the curve for the VLDL, LDL, and HDL
peaks.
Histochemistry—Slides were deparaffinized and then incu-
bated in Oil Red O (Sigma O0652; 0.3 g/ml in 60% isopropyl
alcohol) for 30 min at room temperature. Slides were dipped in
H2O and coverslipped using a generous amount of aqueous
mounting media.
Gene Expression—Gene expression was determined by real
time reverse transcriptase polymerase chain reaction, as
described previously (20), except that a Qiagen lipid kit (74804)
was used. Standard curves weremade from a pool of the cDNA,
and gene expressionwas normalized to 18 S. This allows for the
measurement of relative changes in gene expression within the
indicated experiment. The primer sequences are in Table 1.
LPL FLAG Expression and Activity—Protein extracts were
made in 50 mM Tris, pH 7.4, 500 mM NaCl, 1% Nonidet P-40,
20% glycerol, 1 mM DTT, 10 mM sodium pyrophosphate, 100
mM potassium fluoride, 1 mM EDTA, 1 Calbiochem protease
inhibitors. The protein concentration was determined with a
Bradford assay using BSA as a standard, and 30g was run on a
10% SDS-polyacrylamide gel. The proteins were then trans-
ferred to nitrocellulose, immunoblotted with the indicated
antibody, and quantified with an Odyssey imaging system (LI-
COR Biosciences, Lincoln, NE) as described (21). The antibody
against FLAG (2368) was from Cell Signaling (Danvers MA),
and the antibody against actin (A1978) was from Sigma. Hepa-
rin release from minced adipose tissue and measurement of
LPL activity were done as described (22).
Energy Metabolism Studies—Mice were placed on a high fat
diet for 12 weeks. The mice were then placed in acclimation
chambers for 1week and recorded in aTSE indirect calorimetry
system for 1 week. Resting energy expenditure and net food
intake were determined for the mice during the middle 3 days
and analyzed by an ANCOVA-like model in which energy
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expenditure was regressed against the final lean mass of the
mice and the genotype.
Mass Spectroscopy—Skeletal muscle (gastrocnemius) and
liver lipids were extracted with acidified organic solvents and
analyzed by HPLC/ESI tandemmass spectroscopy as described
(23–25). There were only five control mice in this experiment
because one mouse was an outlier.
Statistics—Except where otherwise indicated, data for the
two groups of mice were analyzed by an unpaired, two-tailed
Student’s t test. The weight gains on HFD and glucose and
insulin tolerance tests were analyzed by repeated measures
ANOVA. The resting energy expenditure and net food intake
data were analyzed by an ANCOVA-like model with data
related to genotype and lean mass, augmented by random
effects to capture correlations among the repeated measure-
ments on any particular animal. Resting respiratory exchange
ratio data were analyzed by ANCOVA. Statistical significance
was defined by a p value less than 0.05. Data analyses were
carried out using Version 9.3 of SAS software, Graph Pad Prism
5, and JMP Version 10 SAS Institute.
RESULTS
Generation of Adipocyte-specific LPL-expressing Transgenic
Mice—Wemade a transgenicmouse that expresses human LPL
under the regulation of the adiponectin 5.4-kb promoter (Fig.
1A), which was previously shown to drive gene expression in
adipocytes in a highly specific manner (18). There were several
foundermice that expressed the transgenemRNA, but only one
expressed detectable protein and was phenotyped. The trans-
gene mRNA is expressed specifically in white adipose tissue
(WAT) depots, but not other tissues (Fig. 1B), and the FLAG-
tagged LPL transgene protein is detected at 56 kilodaltons in
gonadal fat (Fig. 1C). We expected some transgene expression
in brown adipose tissue (BAT) (18), but there was a very low
expression of the transgene in BAT at both themRNA (Fig. 1B)
and protein level (Fig. 1D; no expression detected above back-
ground). This low expression in BAT was not due to an unex-
TABLE 1
Primer sequences
Gene Forward primer Reverse primer
PPAR ACA GGA GAG CAG GGA TTT GC TAC CTA CGC TCA GCC CTC TT
PPAR GGC AGC CTC AAC ATG GAA TG TCG AGC TTC ATG CGG ATT GT
PPAR1/2 AGA CAG ACA TGA GCC TTC ACC GGG TGG GAC TTT CCT GCT AAT
PPAR2 TTC GCT GAT GCA CTG CCT AT GGA ATG CGA GTG GTC TTC CA
Aco TCG AAG CCA GCG TTA CGA G GGT CTG CGA TGC CAA ATT CC
Cpt-1 TCC AGT TGG CTT ATC GTG GTG TCC AGA GTC CGA TTG ATT TTT GC
Total Lpl TTG TGG CCG CCC TGT TCC TCC TCC ATC CAG TTG
Mouse Lpl ACT CGC TCT CAG ATG CCC TA TTG TGT TGC TTG CCA TCC T
CD36 GGC GTG GGT CTG AAG GAC TGG AA GGA GGC ACG GGG TCT CAA CCA
Fabp4 ATG TGT GAT GCC TTT GTG GGA A CTG CCA CTT TCC TTG TGG CAA
Atgl GGT TAG AGT TGC TCA GCC GT ACA TGA GGA GCG GAT GTG TG
Adiponectin CAG TGG ATC TGA CGA CAC CAA ACG TCA TCT TCG GCA TGA CTG
Ucp3 CCG ATT TCA AGC CAT GAT ACG C CCT GGC GAT GGT TCT GTA GG
Scd-1 TTC TTG CGA TAC ACT CTG GTG C CGG GAT TGA ATG TTC TTG TCG T
Pepck AGG AGG GTG TCA TCC GCA AG TGC TTT CGA TCC TGG CCA CA
Angplt4 CAT CCT GGG ACG AGA TGA ACT TGA CAA GCG TTA CCA CAG GC
Sirt1 TGA TTG GCA CCG ATC CTC G CCA CAG CGT CAT ATC ATC CAG
Ucp1 CAA AAA CAG AAG GAT TGC CGA AA TCT TGG ACT GAG TCG TAG AGG
Pgc1 TAT GGA GTG ACA TAG AGT GTG CT CCA CTT CAA TCC ACC CAG AAAG
Glycerol kinase TGA ACC TGA GGA TTT GTC AGC CCA TGT GGA GTA ACG GAT TTC G
Oxidized LDL receptor CCA CAG CAT GGA CGA ATT CA AGC TTG CTT TGT GGC CTT CA
F4/80 TGA CTC ACC TTG TGG TCC TAA CTT CCC AGA ATC CAG TCT TTC C
IL-1 GCA ACT GTT CCT GAA CTC AAC T ATC TTT TGG GGT CCG TCA ACT
Mcp-1 TTA AAA ACC TGG ATC GGA ACC AA GCA TTA GCT TCA GAT TTA CGG GT
LPL transgene AAC TCG ACG GTA TCG ATA GC CTC CTC CAT CCA GTT GAT AA
Atp5a1 TCT CCA TGC CTC TAA CAC TCG CCA GGT CAA CAG ACG TGT CAG
Cyto c CCA AAT CTC CAC GGT CTG TTC ATC AGG GTA TCC TCT CCC CAG
Sdha GGA ACA CTC CAA AAA CAG ACC T CCA CCA CTG GGT ATT GAG TAG AA
Vdac CCC ACA TAC GCC GAT CTT GG GTG GTT TCC GTG TTG GCA GA
FIGURE 1. Transgene design and expression in adipose tissue. A, human
LPL with a C-terminal 3FLAG epitope tag was cloned into a vector contain-
ing the adiponectin 5.4-kb promoter. B,mRNA expression of the transgene in
gonadal (GO), inguinal (SQ), retroperitoneal (RP), brown (BAT) adipose tissues;
skeletal muscle (SKM); and the indicated tissues. C, protein expression of the
transgene in gonadal fat of control and Adipoq-LPL male mice after high fat
diet; the mass of the transgene was estimated using the Bio-Rad Precision
Plus Protein Dual Color standard, which is not shown on the cropped image.
D, protein expression of the transgene in BAT of control and Adipoq-LPLmale
mice after high fat diet; the positive control () is gonadal fat fromanAdipoq-
LPLmouse.
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pected repression of the adiponectin promoter, which drives
the transgene in the Adipoq-LPL mice, because adiponectin
mRNA expression was similar in control andAdipoq-LPL BAT
(see BAT gene expression below). Thus, the AdipoQ-LPL
transgene is expressed in predominantly WAT depots.
Glucose and Insulin Tolerance—We hypothesized that the
Adipoq-LPL mice would have an improved metabolic pheno-
type when challenged with a HFD. When challenged with a
HFD (60% kcal fat), male Adipoq-LPL transgenic mice gained
slightly less weight than their littermate controls (Fig. 2), but
there was no statistically significant difference in weight gain
when analyzed by repeatedmeasures ANOVA (Fig. 2, p 0.21)
or inweight at the end of the study (Table 2; p 0.36). Themale
Adipoq-LPL transgenic mice had improved glucose (Fig. 3A,
p  0.0028) and insulin (Fig. 3B, p  0.028) tolerance. Female
Adipoq-LPL mice had a trend for improved glucose tolerance
(Fig. 3C, p 0.06) but not improved insulin tolerance (Fig. 3D,
p  0.52). There was no statistically significant difference in
glucose (p 0.99) or insulin (p 0.28) tolerance in male mice
on a chow diet (Fig. 3, E and F).
Ectopic Lipid Distribution and Serum Lipids—One mecha-
nism for the improved glucose tolerance could be that
increased adipocyte LPL reduces ectopic lipid accumulation in
liver and muscle by diverting it to fat. We stained liver and
muscle from the HFD-fed male mice with Oil Red O and used
mass spectroscopy to measure DAGs, TGs, and ceramides. As
shown in Fig. 4, there was no qualitative difference inOil RedO
staining between the control and Adipoq-LPL mice in skeletal
muscle (Fig. 4A) or in liver (Fig. 4B). Consistent with this, there
was also no reduction in triglycerides, DAGs, or ceramides in
these tissues in the Adipoq-LPL mice as measured by mass
spectroscopy (Table 3), and theAdipoq-LPLmice in fact had an
increase in liver TGs. There was also no evidence of increased
fat mass or gonadal fat pad weights in the Adipoq-LPL mice
after challenge with HFD (Table 2). Furthermore, serumNEFA
and triglyceride levelswere not significantly reduced in theAdi-
poq-LPL mice. Together, these results suggest that peripheral
tissues are not protected from lipid accumulation in the Adi-
poq-LPL mice. Interestingly, the Adipoq-LPL mice had lower
serum cholesterol levels (Table 2) and lower HDL (p  0.05)
and LDL (p 0.05) when the sera were resolved by size exclu-
sion chromatography (Fig. 5A). We also observed that triglyc-
erides were reduced in the VLDL fraction (Fig. 5B, p  0.05).
Together, these data suggest that the Adipoq-LPL male mice
have reduced lipoprotein levels, but this was not sufficient to
protect peripheral tissues from lipid accumulation.
Improved Adipose Tissue Phenotype—An alternative mecha-
nism of improved insulin sensitivity would be that increased
adipocyte LPL stimulates PPAR transcription factors to
improve adipose tissue function. Therefore, we measured the
expression of PPAR transcription factors and well character-
ized genes that are PPAR-regulated in epididymal adipose tis-
sue. We found that PPAR1/2, PPAR2, and several known
genes regulated by PPAR (CD36, Adipoq, and Fabp4) were all
higher in the epididymal fat of the Adipoq-LPLmice than con-
trol mice after a high fat diet (p  0.05; Table 4). Endogenous
Lpl, which is also PPAR-regulated, was induced 1.3-fold, and
when wemeasured total Lpl by using primers that reacted with
both human andmouseLpl, therewas only a 1.6-fold induction;
thus, the adiponectin promoter only modestly increased total
Lpl mRNA, which could explain why the peripheral tissues
were not protected from ectopic lipid accumulation (see
above).Wemeasured heparin releasable LPL activity and found
that there was an increase in the Adipoq-LPL mice, but it was
not significant (Fig. 6, p 0.13).
Interestingly, neither PPAR- nor the PPAR-regulated
genes Aco, Cpt-1, and Ucp-1 were up-regulated in the Adipoq-
LPLmice (Table 4). PPARwas induced, but Fiaf (Angplt4) and
Sirt1, which are regulated by PPAR, were not induced (Table
4). The expression of a number of mitochondrial genes was not
altered (Table 4). Finally, a number of inflammatory genes (IL-
1, MCP-1, and F4/80) was reduced in the Adipoq-LPL male
mice, but this did not reach significance (Table 4). Thus, the
epididymal fat pads of themaleAdipoq-LPLmice had a pattern
of gene expression driven primarily by PPAR, resulting in
increased Adipoq and reduced inflammation. This pattern of
gene expression was not observed in subcutaneous adipose tis-
sue of the male mice, although Adipoq mRNA expression was
higher in the SQ fat of the Adipoq-LPL mice (1.5-fold; p 
0.113). This togetherwith the increased adiponectin expression
in GO fat resulted in increased serum adiponectin in the male
Adipoq-LPLmice (Table 2).
The female Adipoq-LPLmice did not have increased PPAR
or PPAR-regulated gene (Adipoq and CD36) expression in
their abdominal fat. In fact, endogenous Lpl was decreased in
FIGURE 2.Weight gain of control and Adipoq-LPLmice onHFD.Mice were
fed a HFD as described under “Experimental Procedures” and weighed
weekly. The data are presented asmeans S.E., and the results of a repeated
measures ANOVA are indicated.
TABLE 2
Serum andmouse characterization of male mice
Significant p values are in boldface type.
Parametera Control Adipoq-LPL p
Serum
Fasting glucose (mg/dl) 203.4 3.5 183.1 5.1 0.01
NEFA (mmol/liter) 0.695 0.011 0.670 0.081 0.77
Total triglycerides (mg/dl) 59.42 2.98 50.58 4.84 0.15
Total cholesterol (mg/dl) 166.3 7.2 129.5 4.8 0.01
Insulin (ng/ml) 2.5 0.6 2.8 0.8 0.76
Leptin (ng/ml) 6.9 2.9 7.5 1.4 0.85
Adiponectin (g/ml)b 17.0 1.1 20.9 0.7 0.03
Mouse characterization
Weight at end of study 35.2 1.0 33.1 2.0 0.36
Gonadal fat pad mass 1.04 0.04 1.01 0.04 0.87
Fat mass (ECHOMRI) 13.2 0.9 11.5 1.2 0.29
Lean mass (ECHOMRI) 18.9 0.8 18.8 0.7 0.92
% fat (mean) 41 2 37 2 0.23
a Adipoq-LPL transgenic male mice and their littermate controls were character-
ized in a 19-week high fat (60% cal fat) feeding study (n 6 control and n 6
Adipoq-LPL per group). Data are represented as means S.E.
b n 4 per group because serum was depleted for two mice in each group.
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femaleAdipoq-LPLmice (Table 5). However, there were trends
for decreased inflammatory gene expression, including IL-1
andMCP-1 (p 0.08; Table 5), which were similar to the male
mice. Also, there was no difference in the fat or leanmass of the
control and Adipoq-LPL female mice at the end of the study
(Table 6). These results suggest a different mechanism for the
improved glucose tolerance observed in female Adipoq-LPL
mice.
Mechanism of Insulin Sensitization, Similar to TZD
Treatment?—The increase in PPAR-regulated genes observed
in the Adipoq-LPL mice is similar to pioglitazone treatment
(26). However, there was no increase in weight or adipose mass
(an undesirable side effect of TZD treatment) of the mice
(Table 2), which would be expected if LPL hydrolysis products
stimulated PPAR as potently as TZDs. Because the free fatty
acids produced by LPL are likely weak PPAR agonists (14), we
FIGURE 3.Glucose and insulin tolerance of control andAdipoQ-LPLmice after HFD challenge. Themicewere fed a HFD as described under “Experimental
Procedures.”A, glucose tolerance test ofmalemice after HFD (n 6 control, sixAdipoq-LPL; p 0.0028 by repeatedmeasures ANOVA). B, insulin tolerance test
on the same cohort of mice in A (p 0.028 by repeatedmeasures ANOVA). C, glucose tolerance test of femalemice after HFD (n 6 control, eight Adipoq-LPL;
p 0.06 by repeatedmeasures ANOVA).D, insulin tolerance on the same cohort of female mice in C. E, glucose tolerance test of male mice on chow diet (n
8 control, eight Adipoq-LPL; p 0.99 by repeated measures ANOVA). F, insulin tolerance test on the same cohort of mice in E (p 0.28 by repeated measures
ANOVA). The data are presented as means S.E., and the results of a repeated measures ANOVA are indicated.
FIGURE 4. Ectopic lipids in control and AdipoQ-LPLmice after HFD chal-
lenge.Muscle (A) and liver (B) of control and Adipoq-LPLmale mice from Fig.
2 were stainedwith Oil RedO as described under “Experimental Procedures.”
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determined whether the Adipoq-LPL mice had increased
expression of genes known to require the high potency of
TZDs, including glycerol kinase and the oxidized LDL receptor
(27–29). These were not up-regulated in theAdipoq-LPL trans-
genic mice (Table 4), suggesting that LPL selectively modulates
PPAR to increase insulin sensitivity without side effects of full
PPAR agonism.
Metabolic Phenotype—A recent study suggests that altering
the tissue expression of LPL can affect energy balance (30).
Therefore, we next characterized the mice by indirect calorim-
etry after 12weeks ofHFD challenge; themiceweremaintained
on the HFD while in the calorimetry chambers. The 24-h plots
are shown in Fig. 7. The data were then filtered by time
(between 9:00 a.m. and 6:00 p.m.) and activity (less than 150
counts for the previous 30 min) and then analyzed by
ANCOVA to determine whether resting energy expenditure
was affected by genotype (Fig. 8A). The Adipoq-LPL mice had
increased resting energy expenditure (Fig. 8A, p  0.044),
which was not due to increased activity (Fig. 8B). The increased
energy expenditure was also not due to either WAT browning
(Table 4) or brown fat activation in the Adipoq-LPL mice
because UCP1 and PGC1 were not induced there (Table 7).
Also, PPAR transcription factors and adiponectin were not sig-
nificantly induced in BAT in the Adipoq-LPLmice, suggesting
that the LPL transgene effects are WAT-specific, consistent
with its expression in that depot. The Adipoq-LPL mice
weighed slightly more than the control mice (Fig. 8C, p 
0.016); however, the Adipoq-LPL mice ate more during the
metabolic chamber study, which was significant when the data
were analyzed by ANCOVA using leanmass as a covariate (Fig.
FIGURE 5. FPLC size exclusion chromatography analysis of sera fromcon-
trol and AdipoQ-LPL mice. The sera from the male mice in Fig. 2 were
resolved by size exclusion chromatography, and cholesterol (A) and triglycer-
ides (B) were measured as described under “Experimental Procedures”; the









TG 2.81 0.73 1.97 0.55 0.37
DAG 0.0036 0.0012 0.0028 0.0009 0.58
Ceramide 0.28 0.04 0.40 0.04 0.06
Liver
TG 0.10 0.02 0.34 0.09 0.04
DAG 0.00016 0.00003 0.00044 0.00014 0.22
Ceramide 0.0059 0.0005 0.0057 0.006 0.88
a Tissues from male Adipoq-LPL transgenic mice and their littermate controls
were extracted for lipids and the extracts analyzed by mass spectrometry for
lipids from the liver and muscle as indicated after the 19-week high fat (60% kcal
fat) feeding study (n 5 control and n 6 Adipoq-LPL per group). The data are
means S.E. The values are picomoles/nmol total phosphate.
TABLE 4
Relative gene expression in perigonadal fat frommale mice




PPAR 1.0 0.1 1.2 0.0 1.2 0.47
PPAR 0.9 0.1 1.2 0.1 1.4 0.03
PPAR1/2 0.7 0.0 1.4 0.1 2.0 0.01
PPAR-2 0.9 0.1 1.2 0.0 1.4 0.01
Aco 1.0 0.1 1.0 0.1 1.0 0.53
Cpt-1 1.0 0.1 1.0 0.2 1.0 0.38
Total Lplb 0.8 0.0 1.3 0.2 1.6 0.02
Mouse Lplc 0.9 0.0 1.2 0.1 1.3 0.04
CD36 0.8 0.1 1.4 0.4 1.9 0.02
Fabp4 0.8 0.0 1.3 0.0 1.6 0.01
Atgl 0.9 0.0 1.3 0.0 1.4 0.08
Adiponectin 0.8 0.1 1.4 0.1 1.9 0.01
Ucp3 1.0 0.1 1.7 0.1 1.7 0.08
Scd-1 0.8 0.1 1.5 0.2 1.8 0.02
Pepck 0.8 0.2 1.6 0.5 1.9 0.06
Angplt4 1.0 0.1 1.2 0.2 1.2 0.38
Sirt1 0.9 0.1 1.2 0.1 1.3 0.21
Ucp1 0.8 0.1 0.7 0.1 0.8 0.38
Pgc1 1.2 0.1 1.3 0.1 1.0 0.91
Glycerol kinase 1.6 0.0 1.0 0.2 0.6 0.40
Oxidized LDL receptor 1.2 0.0 1.0 0.2 0.9 0.58
F4/80 1.5 0.2 0.9 0.0 0.6 0.18
IL-1 2.7 2.0 1.0 0.0 0.5 0.37
Mcp-1 2.3 2.1 1.0 0.1 0.5 0.36
Atp5a1 0.9 0.1 1.2 0.1 1.3 0.20
Cyto c 1.0 0.1 1.2 0.0 1.2 0.40
Sdha 0.9 0.1 1.2 0.1 1.3 0.11
Vdac1 1.0 0.1 1.1 0.1 1.2 0.22
a Epididymal fat pads from Adipoq-LPL transgenic mice and their littermate con-
trols were characterized after 19 weeks of a high fat (60% kcal fat) feeding study
(n 6 control; n 6 Adipoq-LPL). The data are presented as means (arbitrary
units) S.E.; the p value is for the difference in the mean.
b Data were measured with a primer set that recognizes human (LPL transgene)
and mouse (endogenous) Lpl.
c Data were measured with a primer set that recognizes mouse (endogenous) Lpl
3UTR.
FIGURE 6. Heparin-releasable LPL activity of epididymal fat of control
andAdipoQ-LPLmice. The heparin-releasable LPL activity in the epididymal
fat of malemice fed an HFDwasmeasured as described under “Experimental
Procedures.” The data are presented as means S.E.
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8D, p 0.001). The resting respiratory exchange ratio was not
different between genotypes (p 0.39).
DISCUSSION
Because LPL generates free fatty acids for TG synthesis in
adipocytes, an expected phenotype of the Adipoq-LPL mice
would be increased adipose mass and relief of lipotoxicity in a
high fat diet challenge. The Adipoq-LPL mice display no phe-
notype on chow and are protected against insulin and glucose
intolerance when challenged with a high fat diet. The mecha-
nism of improvement does not involve reduction of ectopic
lipid accumulation in skeletal muscle or liver; plasma triglycer-
ides andNEFAs were also not reduced in theAdipoq-LPLmice.
Furthermore, theAdipoq-LPLmice do not accumulatemore fat
mass than the control mice; thus there is no evidence for lipid
diversion, which ismost likely explained by themodest increase
in total LPL mRNA by the adiponectin promoter. Rather, the
Adipoq-LPLmice have beneficial adipose tissue phenotype that
is characterized by increased expression of adiponectin and
reduced adipose inflammation. The gene expression profile of
the epididymal fat suggests that the LPL transgene selectively
modulates PPAR activity. This modified adipose phenotype
produces a systemic improvement in metabolism when the
mice are challenged with a high fat diet.
The results of this study suggest that increasing adipocyte
LPL inWAT results in improved glucose and insulin tolerance
in high fat diet-induced obesity. This is the opposite phenotype
of transgenic mice in which LPL was specifically induced in
muscle (muscle-LPL) or liver (liver-LPL), leading to insulin
resistance in those tissues (6). In the muscle-LPL and liver-LPL
models, the increased tissue lipid led to an increase in DAGs
and ceramides in the muscle and liver, respectively. Thus, one
mechanism that we evaluated was whether the Adipoq-LPL
mice had reduced ectopic lipids. However, we found no differ-
ence in Oil Red O staining; TG, DAG, and ceramide levels as
measured by mass spectroscopy; or plasma TG and NEFA.
Consistent with this, there was no increase in fat mass or
gonadal fat pad weight. The lack of lipid redistribution is likely
due to the fact that although the transgene is readily detectable
at both the message and protein level, it is only increasing the
overall message level modestly over endogenous Lpl (Table 4),
and we were not able to demonstrate a significant increase in
heparin releasable activity (Fig. 6). Thus, our transgene expres-
sion is not high enough to cause ectopic lipid redistribution.
Others have shown that increasing LPL globally in rabbits
improves glucose metabolism by reducing serum free fatty
acids (31).
Despite the fact that we did not see a lipid redistribution
effect, we did observe reduced cholesterol. A similar observa-
tion was made by Levak-Frank et al. (32), who found that
increasing muscle LPL expression increased HDL turnover. It
will be interesting to explore themechanism in the future in the
Adipoq-LPLmodel because there have been different reports of
the effect of increasing LPL onHDL in othermodels, with some
models of LPLoverexpressionhaving no change inHDL (31, 33,
34) and one model reporting an increase in HDL (35).
To determine the mechanism for improved glucose metabo-
lism, we evaluated whether the Adipoq-LPL transgene could
improve the WAT phenotype next. We extensively character-
ized gene expression in the WAT of the mice because LPL
hydrolysis products could stimulate PPAR transcription fac-
tors. Activation of these transcription factors in adipocytes
could promote insulin sensitivity by different mechanisms.
Stimulation of PPAR could promote insulin sensitivity by
increasing adiponectin expression and/or other genes involved
in glucose homeostasis (36). PPAR and PPAR could promote
insulin sensitivity by stimulating the -oxidation of fat (37, 38).
We observed that the Adipoq-LPL mice have increased gene
expression of a subset of PPAR-regulated genes. Absent from
this subset are genes that require the high affinity agonism of
TZDs such as glycerol kinase (28, 29). Glycerol kinase produces
glycerol 3-phosphate, which can then be used to re-esterify
fatty acids for storage as triglyceride, promoting weight gain.
Glycerol kinase is not up-regulated in the adipose of Adipoq-
LPL mice, whereas it is up-regulated in the adipose of TZD-
treated mice (29). Also, Ucp1, which is induced by TZDs, was
not up-regulated in the Adipoq-LPL mice. However, Fabp4
(AP2) does not require high affinity ligands for its expression to
be induced (28), and Fabp4 was up-regulated in the Adipoq-
LPL transgenic male mice (Table 4). The results of our studies
suggest that the induction of LPL in adipose tissue increases a
select subset of endogenous PPAR ligands to promote insulin
sensitivitywithout the side effects of high affinity TZDagonists.
This in part explains one of the remarkable features of the Adi-
poq-LPLmice; after high fat diet challenge, their fat mass is not
higher than the controls, which is a predicted side effect of
TZDs and an anticipated phenotype if increasing adipose LPL.
TABLE 5
Relative gene expression in perigonadal fat from female mice




PPAR 1.5 0.4 0.8 0.1 0.6 0.06
PPAR 1.5 0.3 0.8 0.1 0.6 0.05
PPAR .5 0.2 0.3 0.0 0.6 0.12
CD36 1.1 0.1 1.0 0.2 0.9 0.45
Fabp4 1.9 0.5 0.8 0.2 0.4 0.07
Adiponectin 1.2 0.1 1.0 0.2 0.8 0.33
F4/80 0.3 0.0 0.3 0.1 1.0 0.98
IL-1 5.5 1.2 3.0 0.7 0.5 0.08
Mcp-1 2.1 0.7 0.9 0.3 0.4 0.08
a Perigonadal fat pads from female Adipoq-LPL transgenic mice and their litter-
mate controls were characterized after 19 weeks of a high fat (60% kcal fat) feed-
ing study (n 6 control; n 8 Adipoq-LPL). The data are presented as means
(arbitrary units) S.E.; the p value is for the difference in the mean.
TABLE 6
Serum andmouse characterization of female mice
Parametera Control Adipoq-LPL p
Serum
Fasting glucose (mg/dl) 197.4 5.8 195.8 9.9 0.88
Total triglycerides (mg/dl) 204.3 30.0 161.8 21.4 0.26
Total cholesterol (mg/dl) 153.0 19.2 128.9 12.0 0.33
Insulin (ng/ml) 0.53 0.09 0.73 0.17 0.37
Mouse characterization
Weight at end of study 36.3 1.8 34.5 3.0 0.65
Fat mass (ECHOMRI) 16.9 1.3 15.0 2.3 0.53
Lean mass (ECHOMRI) 16.1 0.6 16.1 0.7 0.66
% Fat (mean) 50.9 2.9 46.2 3.4 0.27
a Adipoq-LPL female transgenic mice and their littermate controls were charac-
terized in a 21-week high fat (60% cal fat) feeding study (n 6 control and n 8
Adipoq-LPL per group) that started at age 5 weeks. The data are presented as
means S.E.; the p value is for the difference in the mean.
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FIGURE7.24-henergymetabolismdata fromcontrol andAdipoq-LPLmiceduringHFDchallenge. Themicewere fed ahigh fat diet (60%calories from fat)
for 12 weeks prior to placing them in calorimetry chambers; the data were analyzed as described under “Experimental Procedures.” The mean data for the
control and Adipoq-LPLmice are plotted as a function of time.
FIGURE 8. Characterization of control andAdipoQ-LPLmice in calorimetry chambers duringHFD challenge. A, data from Fig. 7 were filtered by time and
activity and analyzedwith respect to the leanmass of themice. Resting energy expenditurewas plotted against post-leanmass; *,p 0.044. B, average activity
of the mice. C,weight of the mice after the study; *, p 0.016. D, net food intake during the study; *, p 0.001.
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After 12 weeks of HFD challenge, the AdipoQ-LPLmice had
higher energy expenditure than the controls. This response to
the increased LPL could be the result of adipose tissue trying to
defend its ownmass (39) by increasing energy expenditure. The
increased energy expenditure does not involve increased activ-
ity. It also does not involve browning of the WAT depots
because Pgc1 andUcp-1were not increased there. Nor does it
involve BAT activation because Pgc1 and Ucp1 are not
increased in that depot. Also, unexpectedly, the LPL transgene
was not expressed in BAT, suggesting that diversion of lipid to
BAT is not occurring in the Adipoq-LPL mice. Of note, there
was no difference in weight loss while in the acclimation cham-
bers or weight gain while in the metabolic chambers. One pos-
sibility for the increase in energy expenditure would be that the
improvedWATphenotype leads to this by an adipokine such as
adiponectin, which causes increased energy expenditure (40,
41). However, the anti-inflammatory phenotype could be
involved in this. This increase in energy expenditure is the
opposite phenotype to knocking down LPL in neurons (30), but
we did not find the transgene expressed in the brain, so the
mechanism remains to be determined. In addition to the
increase in energy expenditure, the Adipoq-LPL mice con-
sumed more of the high fat diet. Thus, there is a futile cycle of
increased energy expenditure and increased food intake. Nev-
ertheless, this mouse model could thus be a useful tool to
address the mechanism by which adipose defends its ownmass
by increasing energy expenditure in response to increased LPL
in future studies.
In summary, increasing LPL in adipocytes improves adipose
function and protects against glucose and insulin intolerance in
diet-induced obesity. This occurs by the selective induction of
PPAR-regulated genes that lead to systemic improvements in
metabolism and increased energy expenditure. Identifying
these pathways and deciphering their contribution to regula-
tion of metabolism is an important future goal. We are cur-
rently studying the acute response of this mouse model to high
fat diet using microarrays to better understand the mechanism
of the improved adipose phenotype.
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